World's Best Scientists 2026 revealed!
Andrew Grigg

Andrew Grigg

D-Index & Metrics

Medicine

D-Index
76
Citations
20685
World Ranking
18799
National Ranking
630

Overview

Andrew Grigg is affiliated with the Austin Hospital in Australia and has a research focus centered within the field of Medicine, with significant contributions to subfields such as Hematology, Genetics, Pathology and Forensic Medicine, Oncology, and Immunology.

Their work prominently addresses topics related to blood cancers and related disorders. Notable main topics covered in their research include:

  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • Lung Cancer Treatments and Mutations
  • Viral-associated cancers and disorders

Andrew Grigg has published numerous papers in several frequent venues, displaying a focus on hematology and oncology journals. The key publication venues for their work include:

  • Leukemia & Lymphoma / Leukemia and Lymphoma (11 publications)
  • Blood (11 publications)
  • British Journal of Haematology (5 publications)
  • Haematologica (5 publications)
  • Internal Medicine Journal (5 publications)

Their recent papers cover a range of topics in hematology and lymphoma treatment. Selected recent publications include:

  • "Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia," 2020, British Journal of Haematology
  • "Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study," 2021, Haematologica
  • "Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study," 2023, HemaSphere
  • "Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience," 2020, British Journal of Haematology
  • "Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapy," 2020, American Journal of Hematology

Collaboration plays a significant role in Andrew Grigg's research. Frequent coauthors in their body of work include:

  • Eliza A. Hawkes (11 joint publications)
  • Kate Manos (9 joint publications)
  • David M. Ross (8 joint publications)
  • Anthony P. Schwarer (7 joint publications)
  • Nada Hamad (6 joint publications)

Best Publications

  • Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

    Susan Branford;Zbigniew Rudzki;Sonya Walsh;Ian Parkinson

  • High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance.

    Susan Branford;Zbigniew Rudzki;Sonya Walsh;Andrew Grigg

  • Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia

    Harrison Cn;Campbell Pj;Buck G;Wheatley K

  • Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

    David M. Ross;Susan Branford;John F. Seymour;Anthony P. Schwarer

  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

    Camille Abboud;Ellin Berman;Adam Cohen

  • A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease

    Mary E D Flowers;Jane F. Apperley;Koen Van Besien;Ahmet Elmaagacli

  • An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study

    G. M. Mead;M. R. Sydes;J. Walewski;A. Grigg

  • Optimizing Dose and Scheduling of Filgrastim (Granulocyte Colony- Stimulating Factor) for Mobilization and Collection of Peripheral Blood Progenitor Cells in Normal Volunteers

    Andrew P. Grigg;Andrew W. Roberts;Heike Raunow;Sue Houghton

  • All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4)

    Harry J. Iland;Harry J. Iland;Ken Bradstock;Ken Bradstock;Shane G. Supple;Alberto Catalano

  • Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR

    David Ross;Susan Branford;John F Seymour;Anthony Schwarer

  • Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

    Stephen M Ansell;Monique C Minnema;Peter Johnson;John M Timmerman

  • Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations.

    Susan Branford;Zbigniew Rudzki;Ian Parkinson;Andrew Grigg

  • Randomized, Blinded, Placebo-Controlled Phase I Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor With Filgrastim After Dose-Intensive Chemotherapy in Patients With Advanced Cancer

    Russell L. Basser;John E.J. Rasko;Kerrie Clarke;Jonathan Cebon

  • Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantation

    Charles G. Mullighan;Sue Heatley;Kathleen Doherty;Ferenc Szabo

  • FATAL THROMBOTIC EVENTS DURING TREATMENT OF AUTOIMMUNE THROMBOCYTOPENIA WITH INTRAVENOUS IMMUNOGLOBULIN IN ELDERLY PATIENTS

    R.K. Woodruff;A.P. Grigg;F.C. Firkin;I.L. Smith

  • Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.

    Susan Branford;David T. Yeung;Wendy T. Parker;Wendy T. Parker;Nicola D. Roberts

  • Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase.

    S Branford;Z Rudzki;A Harper;A Grigg

  • Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy

    Timothy P. Hughes;Susan Branford;Deborah L. White;John Reynolds

  • In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML

    Deborah White;Verity Saunders;A. Bruce Lyons;Susan Branford

  • Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy.

    A Grigg;C G Begley;C A Juttner;J Szer

Frequent Co-Authors

Jeff Szer
Jeff Szer Peter MacCallum Cancer Centre
John F. Seymour
John F. Seymour Peter MacCallum Cancer Centre
David Ritchie
David Ritchie Peter MacCallum Cancer Centre
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute
Andrew W. Roberts
Andrew W. Roberts Walter and Eliza Hall Institute of Medical Research
Monica A. Slavin
Monica A. Slavin Peter MacCallum Cancer Centre
Kenneth F. Bradstock
Kenneth F. Bradstock Westmead Hospital
Andrew Spencer
Andrew Spencer Monash University
Constantine S. Tam
Constantine S. Tam University of Melbourne
John V. Reynolds
John V. Reynolds Trinity College Dublin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For prospective medical students in the USA, there are many alternative online degrees and career pathways to explore. Online programs offer convenience and flexibility, which is especially vital for working professionals or those with family commitments.

Nursing is one popular route. Candidates aiming for advanced practice roles can consider a 1 year dnp program online, which can accelerate the transition to leadership positions in clinical settings. Those looking to enter nursing quickly might opt for fast track lpn programs online, allowing for rapid entry into the healthcare workforce.

Mental health is another expanding field. The fastest psych np program offers a streamlined way to become a Psychiatric Nurse Practitioner—preparing graduates for critical roles in mental health care.

Not all career pathways require direct patient care. Those interested in the business and administrative side of healthcare may choose from the cheapest mha programs online, gaining essential management skills with lower tuition costs.

Exploring these diverse online programs can help you find the right fit for your lifestyle, budget, and career goals within the healthcare industry.

Best Scientists Citing Andrew Grigg

Trending Scientists